Peripheral Reduction of FGFR4 with Antisense Oligonucleotides Increases Metabolic Rate and Lowers Adiposity in Diet-Induced Obese Mice

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Yu, Xing Xian ^a   Watts, Lynnetta M ^a   Manchem, Vara Prasad ^a   Chakravarty, Kaushik ^a   Monia, Brett P ^a   McCaleb, Michael L ^a   Bhanot, Sanjay ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BILE ACID; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR RECEPTOR 4; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC RESTRICTION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; ENERGY EXPENDITURE; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPOLYSIS; MALE; METABOLIC RATE; MOUSE; NONHUMAN; OBESITY; WEIGHT REDUCTION;

EID: 84880832459     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066923     Document Type: Article

References (42)

1. Hill JO, (2006) Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev 27: 750-761.
2. Saris WH, (2001) Very-low-calorie diets and sustained weight loss. Obes Res 9Suppl 4: 295S-301S.
3. Anderson JW, Konz EC, Frederich RC, Wood CL, (2001) Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 74: 579-584.
4. Leibel RL, Rosenbaum M, Hirsch J, (1995) Changes in energy expenditure resulting from altered body weight. N Engl J Med 332: 621-628.
5. Schoeller DA, (2008) Insights into energy balance from doubly labeled water. Int J Obes (Lond) 32Suppl 7: S72-75.
6. Rosenbaum M, Leibel RL, (2010) Adaptive thermogenesis in humans. Int J Obes (Lond) 34Suppl 1: S47-55.
7. Vetter ML, Faulconbridge LF, Webb VL, Wadden TA, (2010) Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol 6: 578-588.
8. Padwal RS, Majumdar SR, (2007) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369: 71-77.
9. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217-225.
10. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, et al. (2003) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17: 1581-1591.
11. Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, et al. (2006) Identification of a hormonal basis for gallbladder filling. Nat Med 12: 1253-1255.
12. Shin DJ, Osborne TF, (2009) FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 284: 11110-11120.
13. Huang X, Yang C, Luo Y, Jin C, Wang F, et al. (2007) FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 56: 2501-2510.
14. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, et al. (2011) FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 13: 729-738.
15. Tomlinson E, Fu L, John L, Hultgren B, Huang X, et al. (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143: 1741-1747.
16. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603.
17. Bhatnagar S, Damron HA, Hillgartner FB, (2009) Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 284: 10023-10033.
18. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, et al. (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331: 1621-1624.
19. Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, et al. (2005) Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42: 362-371.
20. Pandey SK, Yu XX, Watts LM, Michael MD, Sloop KW, et al. (2007) Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem 282: 14291-14299.
21. Yu XX, Murray SF, Watts L, Booten SL, Tokorcheck J, et al. (2008) Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice. Am J Physiol Endocrinol Metab 295: E436-445.
22. Miyata M, Matsuda Y, Nomoto M, Takamatsu Y, Sato N, et al. (2009) Cholesterol feeding prevents hepatic accumulation of bile acids in cholic acid-fed farnesoid X receptor (FXR)-null mice: FXR-independent suppression of intestinal bile acid absorption. Drug Metab Dispos 37: 338-344.
23. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, et al. (2006) Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 116: 817-824.
24. Harrigan GG, Yates LA, (2006) High-throughput screening, metabolomics and drug discovery. IDrugs 9: 188-192.
25. Harrigan GG, (2006) Metabolic profiling-IBC's inaugural meeting. Using metabolomics to accelerate drug discovery and development. 14-15 November 2005, Durham, NC, USA. IDrugs 9: 28-31.
26. Yu XX, Drackley JK, Odle J, (1997) Rates of mitochondrial and peroxisomal beta-oxidation of palmitate change during postnatal development and food deprivation in liver, kidney and heart of pigs. J Nutr 127: 1814-1821.
27. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, et al. (2007) Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 282: 22678-22688.
28. Heal DJ, Gosden J, Smith SL (2012) What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology.
29. Chakrabarti R, (2009) Pharmacotherapy of obesity: emerging drugs and targets. Expert Opin Ther Targets 13: 195-207.
30. Das SK, Chakrabarti R, (2006) Antiobesity therapy: emerging drugs and targets. Curr Med Chem 13: 1429-1460.
31. Maclean PS, Bergouignan A, Cornier MA, Jackman MR, (2011) Biology's response to dieting: the impetus for weight regain. Am J Physiol Regul Integr Comp Physiol 301: R581-600.
32. Samaha FF, Chou CM, (2009) Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors. Obesity (Silver Spring) 17: 220-225.
33. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, et al. (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345-353.
34. Wiley JL, Burston JJ, Leggett DC, Alekseeva OO, Razdan RK, et al. (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145: 293-300.
35. Christopoulou FD, Kiortsis DN, (2011) An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 36: 10-18.
36. Jones SA, (2012) Physiology of FGF15/19. Adv Exp Med Biol 728: 171-182.
37. Fiorucci S, Mencarelli A, Palladino G, Cipriani S, (2009) Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 30: 570-580.
38. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, et al. (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10: 167-177.
39. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, et al. (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489.
40. Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, et al. (2011) Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 286: 26913-26920.
41. Yu C, Wang F, Kan M, Jin C, Jones RB, et al. (2000) Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 275: 15482-15489.
42. Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, et al. (2011) FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One 6: e17868.